Money first, then save lives

Dr. Weeks’ Comments:   There is a maddening and tragic  “voltage drop”  between when scientific innovations are accomplished and the time it takes for doctors to be allowed to offer the life-saving treatment to patents.  The delay is – not surprisingly – related entirely to money. Once a new treatment is molded into a profitable venture, it is released into the market.  Profit before people. That is why so many “centisble” (safe, effective and cost- effective)  remedies are not endorsed by what we increasingly term “corporate”medicine – (BigPharma, AMA, FDA blessed patented i.e. profitable treatments).   So for the past 6 years, I have been lecturing to medical colleagues about the importance of Corrective Cancer Care and doctoring the cancer STEM cells and not just the relatively harmless cancer TUMOR cells. The tragedy is, the life-saving treatments are natural ….   and therefore not-patentable ….    and therefore NOT profitable  (!!) and therefore,  actively discriminated against by corporate medicine agents.
Now, the wheels of commerce are beginning to turn, profits are being created and so, at last, the treatments for cancer STEM cells will soon be available..   just stay alive for the 10-20 years it takes to bring a new innovation to market.

Stocks in Bullish Zone: ZIOPHARM Oncology (NASDAQ:ZIOP)

On 22 MAY ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s stock on June 6, 2014 reported a increase of 7.77% to the closing price of $4.02. Its fifty two weeks range is $1.80 – $5.58. The overall volume in the last trading session was 1.86 million shares. In its share capital, company has 100.72 million outstanding shares.


Leave a Comment

Your email address will not be published. Required fields are marked *